Rockville’s Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis

Aurinia Pharmaceuticals Inc. (AUPH)
Published on :

VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today, in recognition of World Lupus Day, affirmed its commitment to increasing access to equitable healthcare for individuals living with the autoimmune disease systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of grants to establish community-focused patient navigator programs. LN is one of the most serious and common complications of SLE and affects significantly more Black, Asian, and Hispanic individuals living with SLE than non-Hispanic white individuals with the condition. If left untreated, LN can cause irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.

FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. (AUPH)
Published on :

FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis – LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible [….]